Sarcopenia Treatment Market Report 2026

Sarcopenia Treatment Market Overview

• Sarcopenia Treatment market size has reached to $3.72 billion in 2025 • Expected to grow to $4.97 billion in 2030 at a compound annual growth rate (CAGR) of 6% • Growth Driver: Surge In Malnutrition Boosts Sarcopenia Treatment Market Growth • Market Trend: Biophytis Receives FDA Authorization For Groundbreaking SARA-31 Phase 3 Study • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Sarcopenia Treatment Market?

Sarcopenia treatment refers to medical interventions and lifestyle approaches designed to counteract age-related muscle loss and maintain or improve skeletal muscle mass and function. The treatment is aimed at mitigating age-related muscle loss, improving muscle strength, and enhancing overall physical function and mobility. The main types of sarcopenia treatments include protein supplements, vitamin B12 supplements, vitamin D and calcium supplements, and others. Protein supplements are dietary or bodybuilding supplements that come in the form of protein bars, powders, or shakes and are made from whey, plant, and meat sources. These are used to treat primary sarcopenia and secondary sarcopenia, and they can be administered through several routes, such as oral, parenteral, and enteral. These are sold through various distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others.

What Is The Sarcopenia Treatment Market Growth Forecast?

The sarcopenia treatment market size is expected to see strong growth in the next few years. It will grow to $4.97 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to development of novel pharmacological treatments, increasing focus on early diagnosis and intervention, growing healthcare spending on geriatric care, rising prevalence of chronic diseases affecting muscle health, expanding clinical trials targeting muscle regeneration. Major trends in the forecast period include increasing use of combined pharmacological and exercise-based interventions, growing adoption of nutritional supplementation in sarcopenia management, rising clinical research on myostatin inhibitors and anabolic agents, increased diagnosis of sarcopenia in elderly populations, expanding integration of physical therapy in treatment pathways.

Global Sarcopenia Treatment Market Segmentation

1) By Treatment Type: Protein Supplements, Vitamin B12 Supplements, Vitamin D And Calcium Supplements, Other Treatment Types 2) By Type: Primary Sarcopenia, Secondary Sarcopenia 3) By Route Of Administration: Oral, Parenteral, Enteral 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels Subsegments: 1) By Protein Supplements: Whey Protein, Casein Protein, Soy Protein, Plant-Based Protein 2) By Vitamin B12 Supplements: Cyanocobalamin, Methylcobalamin 3) By Vitamin D And Calcium Supplements: Vitamin D2, Vitamin D3, Calcium Carbonate, Calcium Citrate 4) By Other Treatment Types: Exercise Programs, Hormone Replacement Therapy, Other Nutritional Interventions

What Is The Driver Of The Sarcopenia Treatment Market?

The rise in malnutrition is expected to propel the growth of the sarcopenia treatment market going forward. Malnutrition refers to deficiencies, excesses, or imbalances in a person's intake of energy and nutrients, covering both undernutrition and overweight, obesity, and diet-related noncommunicable diseases. Sarcopenia treatment helps address the coexisting conditions of malnutrition and sarcopenia in older adults through interventions such as nutritional therapy and exercise, aiming to improve muscle mass, strength, and overall nutritional status. For instance, in January 2025, according to a report published by the United States Department of Agriculture, a US-based government department, reported that household food insecurity impacted 17.9% of families with children in 2023, affecting roughly 6.5 million such households. Therefore, the rise in malnutrition is driving the growth of the sarcopenia treatment industry.

Key Players In The Global Sarcopenia Treatment Market

Major companies operating in the sarcopenia treatment market are Pfizer Inc, F Hoffmann La Roche, Merck Sharp And Dohme Corp, AbbVie Inc, Bayer AG, Novartis AG, Sanofi SA, Abbott Laboratories Inc, GlaxoSmithKline plc, Eli Lilly And Company, BASF SE, Nestle Health Science, Haleon Group Of Companies, DSM, Amway Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt Ltd, Nutrafill

Global Sarcopenia Treatment Market Trends and Insights

Major companies operating in the sarcopenia treatment market are increasing their focus on development of multiple advance clinical option study to adhere with better treatment option. A clinical study is a systematic investigation conducted on human subjects to evaluate the safety, efficacy, and/or outcomes of a medical intervention. For instance, in September 2023, Biophytis, a France-based biotechnology company, announced the Food and Drug Administration (FDA) authorization to initiate the SARA-31 Phase 3 study in sarcopenia. The study aims to evaluate the efficacy and safety of Sarconeos (BIO101) in the treatment of sarcopenic patients at risk of motor disability. This study demonstrates a significant advancement in technological and pharmaceutical treatment approaches, offering potential efficacy and safety benefits for severe sarcopenic patients. It is the first-ever phase 3 study in sarcopenia and has received FDA authorization. The study will include around 900 patients aged over 65 with sarcopenia, low walking speed, and low hand grip strength. The primary endpoint will be the assessment of the risk of major mobility disability (MMD), walking speed, hand grip strength, and patient-reported quality of life.

What Are Latest Mergers And Acquisitions In The Sarcopenia Treatment Market?

In August 2023, Eli Lilly and Company, a US-based pharmaceutical company, acquired Versanis Bio for a deal of $1.925 billion. As a result of the acquisition, Lilly's portfolio now includes Versanis' leading asset, bimagrumab. This drug is currently undergoing a Phase 2b study both as a standalone treatment and in combination with semaglutide for adults with overweight or obesity. Versanis Bio is a US-based biotechnology company involved in the development of treatments for sarcopenia.

Regional Outlook

North America was the largest region in the sarcopenia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Sarcopenia Treatment Market?

The sarcopenia treatment market consists of revenues earned by entities by providing nutritional therapy, combination therapy, and muscle strength. The market value includes the value of related goods sold by the service provider or included within the service offering. The sarcopenia market also includes sales of muscle stimulators, orthopedic braces and supports, joint replacement implants, anabolic agents, and more. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sarcopenia Treatment Market Report 2026?

The sarcopenia treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sarcopenia treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.